Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2023 16:01 ET | Source: Vor Biopharma

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Initial clinical data supports founding vision that engineered hematopoietic stem cells can enable treatment options after AML transplantAdditional trem-cel data expected by year-end 2023; VCAR33ALLO...
February 21, 2023 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
February 16, 2023 12:00 ET | Source: Vor Biopharma

First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Trem-cel exhibited robust engraftment five months post-transplant through three cycles of MylotargMylotarg treatment enriched CD33-negative donor hematopoiesisSecond patient successfully received...
January 19, 2023 08:00 ET | Source: Vor Biopharma

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in...
January 12, 2023 08:00 ET | Source: Vor Biopharma

Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference

CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley...
December 07, 2022 07:45 ET | Source: Vor Biopharma

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private...
December 07, 2022 07:30 ET | Source: Vor Biopharma

First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Trem-cel (formerly VOR33) successfully manufactured and engrafted normallyBlood counts successfully maintained following post-transplant treatment with MylotargConference call scheduled for today,...
November 22, 2022 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
November 10, 2022 16:15 ET | Source: Vor Biopharma

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Initial clinical data for VOR33 on track for Q4 2022Eyal C. Attar, M.D. appointed as Chief Medical OfficerInitiated in-house clinical manufacturing at Cambridge, MA headquarters CAMBRIDGE, Mass.,...
November 01, 2022 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...